

SUPPLEMENTARY MATERIAL

TABLE S 1: DETAILED BASE-CASE RESULTS OF THE COST-UTILITY ANALYSIS

Results (per capita)	No vaccination	With HRV	Difference
RVGE-related events			
Homecare-RVGE	0.007108	0.003425	-52%
Outpatient-RVGE	0.021259	0.010243	-52%
Inpatient-RVGE	0.015498	0.004213	-73%
RVGE-related death	0.000034	0.000001	-96%
Costs; THB (USD)^a			
<i>Vaccination costs</i>			
All perspectives ^b	0 (0)	141 (4)	141 (4)
<i>Total direct medical costs</i>			
All perspectives ^b	82 (2)	26 (1)	-56 (-2)
<i>Total direct non-medical costs</i>			
Societal perspective (base-case perspective)	57 (2)	22 (1)	-34 (-1)
Societal perspective excluding productivity losses	5 (0)	2 (0)	-3 (0)
Healthcare perspective	N/A	N/A	N/A
<i>Total costs</i>			
Societal perspective (base-case perspective)	138 (4)	190 (6)	51 (2)
Societal perspective excluding productivity losses	87 (3)	169 (5)	82 (2)
Healthcare perspective	82 (2)	167 (5)	86 (3)
Discounted health outcomes			
<i>Net QALY loss</i>	0.001120	0.000092	-0.001027
<i>Net LY loss</i>	0.001009	0.000037	-0.000971
<i>ICER; THB (USD) per QALY gained</i>			
Societal perspective (base-case perspective)	49,923 (1,471)		
Societal perspective excluding productivity losses	80,126 (2,361)		
Healthcare perspective	83,351 (2,456)		
Undiscounted health outcomes			
<i>Net QALY loss</i>	0.002393	0.000140	-0.002253
<i>Net LY loss</i>	0.002539	0.000094	-0.002445
<i>ICER; THB (USD) per QALY gained</i>			
Societal perspective (base-case perspective)	22,763 (671)		

Societal perspective excluding productivity losses	36,535 (1,076)
Healthcare perspective	38,005 (1,120)

^a The annual 2017 exchange rate (THB 33.9385/USD) was applied [59]

^b The relevant estimates were the same for all the perspectives considered i.e.(i) societal perspective (base-case perspective), (ii) societal perspective excluding productivity losses, and (iii) healthcare perspective

HRV: human rotavirus vaccine; ICER: incremental cost-effectiveness ratio; LY: life-year; N/A: not applicable;

QALY: quality-adjusted life year; RVGE: rotavirus gastroenteritis; THB: Thai baht; USD: United States dollar

TABLE S 2: DETAILED RESULTS OF THE COST-UTILITY SCENARIO ANALYSES

Results (per capita)	No vaccination	With HRV	Difference			
Vaccine effectiveness scenario analysis based on Tharmaphornpilas et al. 2017 [25]						
<i>RVGE-related events</i>						
Homecare-RVGE	0.007108	0.003425	-52%			
Outpatient-RVGE	0.021259	0.010243	-52%			
Inpatient-RVGE	0.015498	0.001996	-87%			
RVGE-related death	0.000034	0.000002	-93%			
<i>Costs; THB (USD)</i>						
Vaccination costs	0 (0)	141 (4)	141 (4)			
Total direct medical costs	82 (2)	17 (0)	-65 (-2)			
Total direct non-medical costs	57 (2)	19 (1)	-38 (-1)			
Total costs	138 (4)	177 (5)	39 (1)			
<i>Discounted health outcomes</i>						
Net QALY loss	0.001120	0.000114	-0.001006			
Net LY loss	0.001009	0.000070	-0.000939			
ICER; THB (USD) per QALY gained	38,410 (1,132)					
<i>Undiscounted health outcomes</i>						
Net QALY loss	0.002393	0.000202	-0.002190			
Net LY loss	0.002539	0.000176	-0.002363			
ICER; THB (USD) per QALY gained	17,637 (520)					
Direct medical costs scenario analysis based on Tharmaphornpilas et al. 2015 [26]						
<i>Costs; THB (USD)^a</i>						
Vaccination costs	0 (0)	141 (4)	141 (4)			
Total direct medical costs	115 (3)	34 (1)	-81 (-2)			
Total direct non-medical costs	57 (2)	22 (1)	-34 (-1)			
Total costs	172 (5)	197 (6)	26 (1)			
<i>Discounted health outcomes</i>						
Net QALY loss	0.001120	0.000092	-0.001027			
Net LY loss	0.001009	0.000037	-0.000971			
ICER; THB (USD) per QALY gained	25,037 (738)					
<i>Undiscounted health outcomes</i>						
Net QALY loss	0.002393	0.000140	-0.002253			
Net LY loss	0.002539	0.000094	-0.002445			
ICER; THB (USD) per QALY gained	11,416 (336)					

^a The annual 2017 exchange rate (THB 33.9385/USD) was applied [59].

HRV: human rotavirus vaccine; ICER: incremental cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted life year; RVGE: rotavirus gastroenteritis; THB: Thai baht; USD: United States dollar

**TABLE S 3: DETAILED BASE-CASE RESULTS OF THE BUDGET
IMPACT ANALYSIS**

Costs; THB (USD)	Year				
	2019	2020	2021	2022	2023
No vaccination					
Vaccination costs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Outpatient visit costs	50,374,674 (1,484,293)	48,947,434 (1,442,239)	47,556,018 (1,401,241)	46,200,746 (1,361,308)	44,884,097 (1,322,513)
Hospitalisation costs	199,435,083 (5,876,367)	193,791,539 (5,710,080)	188,282,845 (5,547,766)	182,917,079 (5,389,663)	177,704,230 (5,236,066)
Total costs	249,809,757 (7,360,660)	242,738,973 (7,152,319)	235,838,863 (6,949,007)	229,117,825 (6,750,971)	222,588,327 (6,558,579)
With HRV					
Vaccination costs	457,706,645 (13,486,355)	444,662,724 (13,102,015)	431,990,534 (12,728,628)	419,679,482 (12,365,882)	407,719,276 (12,013,474)
Outpatient visit costs	40,384,255 (1,189,925)	31,890,443 (939,654)	27,316,019 (804,868)	24,045,930 (708,515)	21,519,565 (634,075)
Hospitalisation costs	177,182,966 (5,220,707)	117,696,167 (3,467,925)	85,098,706 (2,507,439)	61,541,865 (1,813,335)	48,173,521 (1,419,436)
Total costs	675,273,866 (19,896,986)	594,249,334 (17,509,593)	544,405,260 (16,040,935)	505,267,278 (14,887,732)	477,412,362 (14,066,985)
Difference HRV versus no vaccination					
Vaccination costs	457,706,645 (13,486,355)	444,662,724 (13,102,015)	431,990,534 (12,728,628)	419,679,482 (12,365,882)	407,719,276 (12,013,474)
Outpatient visit costs	-9,990,419 (-294,368)	-17,056,991 (-502,585)	-20,239,999 (-596,373)	-22,154,816 (-652,793)	-23,364,532 (-688,437)
Hospitalisation costs	-22,252,117 (-655,660)	-76,095,372 (-2,242,155)	-103,184,139 (-3,040,327)	-121,375,214 (-3,576,328)	-129,530,708 (-3,816,630)
Total difference	425,464,109 (12,536,326)	351,510,361 (10,357,275)	308,566,397 (9,091,928)	276,149,452 (8,136,761)	254,824,035 (7,508,406)
Cumulative difference	425,464,109 (12,536,326)	776,974,470 (22,893,601)	1,085,540,867 (31,985,529)	1,361,690,319 (40,122,289)	1,616,514,354 (47,630,695)

HRV: human rotavirus vaccine; THB: Thai baht; USD: United States dollar

**TABLE S 4: DETAILED RESULTS OF THE BUDGET IMPACT
SCENARIO ANALYSIS**

Costs; THB (USD)	Year				
	2019	2020	2021	2022	2023
No vaccination					
Vaccination costs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Outpatient visit costs	50,374,674	48,947,434	47,556,018	46,200,746	44,884,097
	(1,484,293)	(1,442,239)	(1,401,241)	(1,361,308)	(1,322,513)
Hospitalisation costs	199,435,083	193,791,539	188,282,845	182,917,079	177,704,230
	(5,876,367)	(5,710,080)	(5,547,766)	(5,389,663)	(5,236,066)
Total costs	249,809,757	242,738,973	235,838,863	229,117,825	222,588,327
	(7,360,660)	(7,152,319)	(6,949,007)	(6,750,971)	(6,558,579)
With HRV					
Vaccination costs	274,623,987	303,140,639	334,618,429	369,364,838	407,719,276
	(8,091,813)	(8,932,058)	(9,859,553)	(10,883,358)	(12,013,474)
Outpatient visit costs	44,380,423	37,919,976	33,182,018	28,839,191	24,615,081
	(1,307,672)	(1,117,314)	(977,710)	(849,749)	(725,285)
Hospitalisation costs	186,083,813	146,367,444	118,379,865	93,076,454	71,565,955
	(5,482,971)	(4,312,726)	(3,488,070)	(2,742,503)	(2,108,695)
Total costs	505,088,223	487,428,060	486,180,312	491,280,483	503,900,312
	(14,882,456)	(14,362,098)	(14,325,333)	(14,475,610)	(14,847,454)
Difference HRV versus no vaccination					
Vaccination costs	274,623,987	303,140,639	334,618,429	369,364,838	407,719,276
	(8,091,813)	(8,932,058)	(9,859,553)	(10,883,358)	(12,013,474)
Outpatient visit costs	-5,994,251	-11,027,458	-14,374,000	-17,361,555	-20,269,017
	(-176,621)	(-324,925)	(-423,531)	(-511,559)	(-597,228)
Hospitalisation costs	-13,351,270	-47,424,095	-69,902,979	-89,840,625	-106,138,275
	(-393,396)	(-1,397,354)	(-2,059,696)	(-2,647,160)	(-3,127,371)
Total difference	255,278,465	244,689,087	250,341,450	262,162,658	281,311,984
	(7,521,796)	(7,209,779)	(7,376,326)	(7,724,639)	(8,288,875)
Cumulative difference	255,278,465	499,967,552	750,309,002	1,012,471,659	1,293,783,644
	(7,521,796)	(14,731,575)	(22,107,901)	(29,832,540)	(38,121,415)

HRV: human rotavirus vaccine; THB: Thai baht; USD: United States dollar